← Leaderboards
Ge Liu
Vaxinnate Corporation
$1,151,127
Attributed
$2,302,253
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $754.1K · FY2013–16$1M$750K$500K$250K$0
'13
'14
'15
'16
Funding mix
By agency
NIH$2,302,253 · 2
By mechanism
R01$2,183,992 · 1
R21$118,261 · 1
Top collaborators
- Lynda G Tussey4 shared
Most similar at Vaxinnate Corporation
Same institution · by research overlap
- Lynda G Tussey$1,451,127
- Albert Price$298,530
Others in their field
Top investigators on “Immune Sera”
- Ignacio E. Sanz · University Of Rochester$26,794,157
- William Martin Gelbart · Harvard University$18,341,635
- Mikael Knip · University Of Helsinki$16,834,161
- Jiri F Mestecky · University Of Alabama At Birmingham$16,162,451
- Gregory S Hageman · University Of Iowa$14,773,700
- Dorothy J Becker · Children'S Hosp Pittsburgh/Upmc Hlth Sys$13,640,541
Research focus
Immune SeraImmunogenicityFlagellinImmune ResponseImmunizationImmunogenicCytokineFeverFlavivirusImmuneElderlyAttenuatedImmunization ScheduleImmunocompromised HostAdjuvantCountryBaseEvaluationAntigensDengueChildAgonistDoseLead
Grant awards (4)
Development of a Recombinant Zika Virus Vaccine Based on Subunit Envelope (E) Amtigen Fused to a TLR5 Agonist (Flagellin)$118,261
R21 · FY2016 · AI · contact PI
Development of a Recombinant Tetravalent Dengue Vaccine Based on a Subunit Envelo$754,080
R01 · FY2015 · AI · contact PI
Development of a Recombinant Tetravalent Dengue Vaccine Based on a Subunit Envelo$683,222
R01 · FY2014 · AI · contact PI
Development of a Recombinant Tetravalent Dengue Vaccine Based on a Subunit Envelo$746,690
R01 · FY2013 · AI · contact PI